Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Meet Mohsen Nemat-Gorgani, PhD, member of the SGTC Team

On this #OMFScienceWednesday we are pleased to introduce you to a central member of the OMF-funded ME / CFS Collaborative Research Center team at the Stanford Genome Technology Center (SGTC), Mohsen Nemat-Gorgani, PhD.  Dr. Nemat-Gorgani is leading a team to investigate the Red Blood Cells (RBC) in ME / CFS patients. Mohsen shared his story with OMF.

Mohsen Nemat-Gorgani, PhD, member of the SGTC team

I was born and raised in Iran and did my undergraduate and graduate studies in U.K. In 1974, I obtained a PhD in biochemistry from Warwick University, and after a year of postdoctoral training at Vanderbilt, I returned to Iran. In October 2003, I came to the Stanford Genome Technology Center (SGTC) as a Visiting Professor from Tehran University and continued working as a Research Associate upon termination of the sabbatical leave. During my time at the Center, I participated in various technology development projects, and about two years ago, after a brief absence from the Center, I started working on ME / CFS.

Upon participation in the ME / CFS project, and during the first few months of my presence at the Center, I learnt, mainly by talking to Ron Davis, Laurel Crosby and a number of patients, that inadequate blood flow to tissues could be the cause of some of the symptoms reported in ME / CFS. It also became known to me that red blood cells (RBCs) and their mechanical properties may largely determine the rheological (deformation and flow) behavior of blood in normal and disease states.

Interestingly, a few years before working on ME / CFS, I was somewhat involved in a study on the mechanical properties of breast cancer cells at the Center. This work was conducted by Shane Crippen, a graduate student under the guidance of Ron Davis, Roger Howe and Stefanie Jeffrey (Electrical Engineering and Stanford Medical School, respectively). In the course of subsequent discussions (in June 2016) with Ron and Roger, it was decided that we should look at the mechanical properties of RBCs related to ME / CFS, and we started exploring different technical approaches to achieve this goal.

In January 2017, during a visit to SJSU, I met Anand Ramasubramanian who had recently taken up a faculty position in the Chemical and Materials Engineering Department. Anand had previously looked at deformability of monocytes using a microfluidic platform, and during the course of our discussions, it became obvious that a collaboration with his team (involving Amit Saha, who had worked with Anand on monocyte deformability as a part of his Ph.D. thesis, and graduate students) would be an effective way of going forward. A few months later, the studies were initiated, and with the outstanding technical support provided by Julie Wilhelmy and Layla Cervantes, samples from a large number (over 30) of ME / CFS patients and healthy controls were collected at the SGTC, and later analyzed at SJSU.

RBC deformability is believed to play an important role in their main function – the transport of oxygen and carbon dioxide via blood circulation. They are highly elastic, which allows them to flow easily. The reason for this exceptional property is found in the composition of the membrane and the membrane-cytoskeleton interaction. A healthy RBC is approximately 8.0 µm in diameter, which needs to undergo large deformations in order to pass through capillaries, around 2-3 µm in diameter.  A slight decrease in deformability has been shown to cause a significant increase in microvascular flow resistance, with important physiological implications.

RBC deformability has been shown to be impaired in various pathologies including inflammatory conditions such as sepsis. Recent studies have clearly indicated that inflammation is involved in ME / CFS. Moreover, RBCs are highly susceptible to oxidative stress due to the high contents of polyunsaturated fatty acids in the cell membrane, a process that may impair deformability, and some studies have indicated RBC oxidative damage occurring in ME / CFS.

Using the microfluid platform, the mechanical properties of RBCs from ME / CFS and healthy control samples have been compared by determination of the time taken to enter the channels as well as transit velocity, and elongation capacity. Our preliminary results suggest clear differences in deformability of RBCs from ME / CFS and healthy control blood samples using this platform. A manuscript has recently been submitted for publication describing these observations.

Studies underway include biochemical analyses, membrane fluidity determination, lipidomics analysis, atomic force microscopy (AFM), scanning electron microscopy, zeta potential and simulation studies.

In recent months, we have established collaborations with other groups including the following:

  1.  Andrey Malkovskiy, PhD, Stanford School of Medicine, and the Stanford Nano Shared Facilities (AFM studies).
  2.  Vinny Chandran Suja, graduate student, Chemical Engineering, Stanford (zeta potential studies).
  3. Eric Shaqfeh, PhD, Professor, and Amir Saadat, Postdoctoral Scholar, Chemical Engineering, Stanford (simulation studies).

The zeta potential and related studies are expected to be in collaboration with Gerald Fuller’s group (Professor, Chemical Engineering, Stanford).

Financial support for all these efforts has been provided by OMF. It is hoped that differences in RBC mechanical properties will serve as a label-free biomarker in CFS diagnosis. We hope the described collaborative efforts will help us develop a diagnostic device for ME / CFS.

It is a great pleasure and privilege to be part of Ron’s team, and to try to contribute toward solving the mystery of ME / CFS.

Thank you, Mohsen for providing us with a detailed look into the potential effects of RBC alterations and for leading a stellar team. We sincerely appreciate your work with Dr. Davis.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo